Form 4: Sangamo Therapeutics Executive Reports Stock Disposals for Tax Obligations
SEC Form 4 Filing
Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of shares to cover tax obligations related to vesting restricted stock units.
Summary
- Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, filed a Form 4 detailing the disposal of company stock.
- The disposals were not discretionary trades but were made to cover mandatory tax withholding obligations related to the vesting of restricted stock units (RSUs).
- On November 24, 2024, 721 shares were disposed of at a price of $1.88 per share.
- On November 25, 2024, 505 shares were disposed of at a price of $1.94 per share.
- These transactions reduced Davis's holdings to 202,368 shares after the first transaction and 201,863 shares after the second transaction.
- The remaining shares are subject to vesting schedules from previous RSU grants.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral event related to executive compensation.
Risks
- The document indicates that the executive's stock holdings are subject to vesting schedules, which could be impacted by changes in the company's performance or the executive's continued service.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing is typical for executives who receive stock-based compensation.
Comparison to Industry Standards
- The filing is consistent with standard practices for reporting insider transactions in publicly traded companies.
- Many biotechnology companies use restricted stock units as part of their compensation packages, and the tax withholding process is a common reason for stock disposals by executives.
Stakeholder Impact
- The stock disposals are unlikely to have a significant impact on shareholders as they are related to tax obligations and not discretionary sales.
Key Dates
| Date | Description |
|---|---|
| 11/24/2024 | Date of the first stock disposal for tax obligations. |
| 11/25/2024 | Date of the second stock disposal for tax obligations. |
| 11/26/2024 | Date the Form 4 was signed. |
Keywords
Form 4, Sangamo Therapeutics, stock disposal, restricted stock units, tax withholding, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.